Tscan Therapeutics Stock Technical Analysis
| TCRX Stock | USD 0.93 0.04 4.12% |
As of the 15th of February 2026, Tscan Therapeutics has the Coefficient Of Variation of (4,222), variance of 25.24, and Risk Adjusted Performance of (0.01). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tscan Therapeutics, as well as the relationship between them.
Tscan Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Tscan, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to TscanTscan Therapeutics' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Tscan Therapeutics Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 6.0 | Strong Buy | 8 | Odds |
Most Tscan analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tscan stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tscan Therapeutics, talking to its executives and customers, or listening to Tscan conference calls.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tscan Therapeutics. If investors know Tscan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tscan Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.12) | Revenue Per Share | Quarterly Revenue Growth 1.394 | Return On Assets | Return On Equity |
Understanding Tscan Therapeutics requires distinguishing between market price and book value, where the latter reflects Tscan's accounting equity. The concept of intrinsic value - what Tscan Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Tscan Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tscan Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tscan Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tscan Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Tscan Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tscan Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tscan Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Tscan Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Tscan Therapeutics or generate 0.0% return on investment in Tscan Therapeutics over 90 days. Tscan Therapeutics is related to or competes with Acrivon Therapeutics, Relmada Therapeutics, Lite Strategy, Adicet Bio, Immunic, Pmv Pharmaceuticals, and Vaxart. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell ther... More
Tscan Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tscan Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tscan Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 23.74 | |||
| Value At Risk | (6.86) | |||
| Potential Upside | 11.93 |
Tscan Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tscan Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tscan Therapeutics' standard deviation. In reality, there are many statistical measures that can use Tscan Therapeutics historical prices to predict the future Tscan Therapeutics' volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.04) |
Tscan Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.03) | |||
| Mean Deviation | 3.62 | |||
| Coefficient Of Variation | (4,222) | |||
| Standard Deviation | 5.02 | |||
| Variance | 25.24 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.04) | |||
| Maximum Drawdown | 23.74 | |||
| Value At Risk | (6.86) | |||
| Potential Upside | 11.93 | |||
| Skewness | 0.9284 | |||
| Kurtosis | 1.54 |
Tscan Therapeutics Backtested Returns
At this stage we consider Tscan Stock to be very risky. Tscan Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of close to zero, which indicates the firm had a close to zero % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Tscan Therapeutics, which you can use to evaluate the volatility of the company. Please validate Tscan Therapeutics' Risk Adjusted Performance of (0.01), variance of 25.24, and Coefficient Of Variation of (4,222) to confirm if the risk estimate we provide is consistent with the expected return of 0.0354%. The entity has a beta of 3.29, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Tscan Therapeutics will likely underperform. Tscan Therapeutics right now has a risk of 4.65%. Please validate Tscan Therapeutics coefficient of variation, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Tscan Therapeutics will be following its existing price patterns.
Auto-correlation | 0.39 |
Below average predictability
Tscan Therapeutics has below average predictability. Overlapping area represents the amount of predictability between Tscan Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tscan Therapeutics price movement. The serial correlation of 0.39 indicates that just about 39.0% of current Tscan Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.39 | |
| Spearman Rank Test | 0.28 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Tscan Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Tscan Therapeutics Technical Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Normalized Average True Range is used to analyze tradable apportunities for Tscan Therapeutics across different markets.
About Tscan Therapeutics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Tscan Therapeutics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Tscan Therapeutics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Tscan Therapeutics price pattern first instead of the macroeconomic environment surrounding Tscan Therapeutics. By analyzing Tscan Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Tscan Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Tscan Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 6.51 | 8.14 | 9.36 | 9.05 | Net Debt To EBITDA | 0.51 | 0.68 | 0.78 | 0.74 |
Tscan Therapeutics February 15, 2026 Technical Indicators
Most technical analysis of Tscan help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Tscan from various momentum indicators to cycle indicators. When you analyze Tscan charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.03) | |||
| Mean Deviation | 3.62 | |||
| Coefficient Of Variation | (4,222) | |||
| Standard Deviation | 5.02 | |||
| Variance | 25.24 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.04) | |||
| Maximum Drawdown | 23.74 | |||
| Value At Risk | (6.86) | |||
| Potential Upside | 11.93 | |||
| Skewness | 0.9284 | |||
| Kurtosis | 1.54 |
Tscan Therapeutics February 15, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Tscan stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.05 | ||
| Daily Balance Of Power | (0.80) | ||
| Rate Of Daily Change | 0.96 | ||
| Day Median Price | 0.96 | ||
| Day Typical Price | 0.95 | ||
| Price Action Indicator | (0.04) | ||
| Market Facilitation Index | 0.05 |
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.